News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
690,930 Results
Type
Article (40134)
Company Profile (285)
Press Release (650511)
Section
Business (206336)
Career Advice (1996)
Deals (35759)
Drug Delivery (83)
Drug Development (81000)
Employer Resources (168)
FDA (16275)
Job Trends (14917)
News (347983)
Policy (32746)
Tag
Academia (2573)
Alliances (49923)
Alzheimer's disease (1203)
Approvals (16192)
Artificial intelligence (111)
Bankruptcy (356)
Best Places to Work (11487)
Biotechnology (196)
Breast cancer (92)
Cancer (812)
Career advice (1666)
Cell therapy (184)
Clinical research (63889)
Collaboration (281)
Compensation (154)
COVID-19 (2539)
Cystic fibrosis (79)
Data (712)
Diabetes (120)
Diagnostics (6443)
Drug pricing (73)
Earnings (84659)
Employer resources (145)
Events (109758)
Executive appointments (227)
FDA (16668)
Funding (258)
Gene therapy (137)
GLP-1 (548)
Government (4357)
Healthcare (18838)
Infectious disease (2604)
Inflammatory bowel disease (98)
Interviews (309)
IPO (16400)
Job creations (3683)
Job search strategy (1427)
Layoffs (408)
Legal (7899)
Lung cancer (143)
Manufacturing (140)
Medical device (13260)
Medtech (13265)
Mergers & acquisitions (19332)
Metabolic disorders (334)
Neuroscience (1431)
NextGen Class of 2024 (6531)
Non-profit (4517)
Northern California (1088)
Obesity (202)
Opinion (176)
Patents (89)
People (56723)
Phase I (19802)
Phase II (28139)
Phase III (21009)
Pipeline (184)
Postmarket research (2557)
Preclinical (8435)
Radiopharmaceuticals (241)
Rare diseases (172)
Real estate (5980)
Regulatory (21635)
Research institute (2347)
Resumes & cover letters (350)
Southern California (1013)
Startups (3641)
United States (10824)
Vaccines (521)
Weight loss (151)
Date
Today (156)
Last 7 days (586)
Last 30 days (2682)
Last 365 days (36410)
2024 (29444)
2023 (40430)
2022 (51549)
2021 (56107)
2020 (54586)
2019 (46975)
2018 (35405)
2017 (32526)
2016 (31989)
2015 (38123)
2014 (31796)
2013 (26920)
2012 (29106)
2011 (29799)
2010 (27788)
Location
Africa (729)
Arizona (185)
Asia (37720)
Australia (6172)
California (2490)
Canada (1124)
China (191)
Colorado (108)
Connecticut (106)
Europe (81381)
Florida (355)
Georgia (94)
Illinois (298)
Indiana (169)
Kansas (96)
Maryland (482)
Massachusetts (2012)
Michigan (140)
Minnesota (249)
New Jersey (749)
New York (766)
North Carolina (674)
Northern California (1088)
Ohio (120)
Pennsylvania (712)
South America (1109)
Southern California (1013)
Texas (344)
Utah (72)
Washington State (298)
690,930 Results for "amydis diagnostics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Amydis to Present First Ocular Tracer Designed to Detect Transthyretin Amyloidosis (ATTR) at AAOOP Conference
October 10, 2024
·
3 min read
Drug Development
Amydis Launches Phase 2 Glaucoma Clinical Program Using Novel Retinal Tracer to Detect Amyloid Beta
Amydis Inc. announced it has launched a Phase 2 clinical program for its novel retinal tracer, AMDX-2011P, to detect amyloid-beta in glaucoma patients.
November 2, 2023
·
3 min read
Co-Diagnostics, Inc. to Participate at FIME 2024 in Miami Beach, June 19-21
Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has been invited to participate in the Utah booth at the FIME trade show in Miami Beach, Florida, on June 19-21.
June 18, 2024
·
1 min read
Business
Co-Diagnostics, Inc. Reports First Quarter 2024 Financial Results
Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced financial results for the quarter ended March 31, 2024.
May 9, 2024
·
10 min read
Biotech Beach
Amydis Receives $3.4 million NIH Commercialization Readiness Pilot Grant Award to Map Heterogeneity of Alzheimer’s Diseases in Human Clinical Trial Using Novel Retinal Tracer
Amydis Inc., a privately held clinical-stage company pioneering a platform of ocular tracers to enable imaging of disease biomarkers in the eye, announced that it has received a two-year Commercialization Readiness Pilot Program grant award of $3.4 million from The National Institutes of Health.
November 14, 2023
·
3 min read
Business
Co-Diagnostics, Inc. Announces First Quarter 2024 Earnings Release Date and Webcast
Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2024 financial results on Thursday, May 9, 2024, after the market close.
April 25, 2024
·
1 min read
Press Releases
Bracco Diagnostics Inc. and Subtle Medical Announce FDA Clearance of AiMIFY™ Software for Enhanced MRI
October 17, 2024
·
4 min read
News
Co-Diagnostics, Inc. to Host Booth at Medlab Africa in Cape Town on Oct 22-24, 2024
October 21, 2024
·
3 min read
Policy
Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform
Co-Diagnostics, Inc. announced that the Company has completed its first U.S. Food and Drug Administration application for 510 clearance for the Co-Dx™ PCR Pro™ instrument, and the Co-Dx PCR COVID-19 Test for over-the-counter use.
June 14, 2024
·
4 min read
Business
Co-Diagnostics, Inc. Reports Full Year 2023 Financial Results
Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the full year ended December 31, 2023.
March 14, 2024
·
11 min read
1 of 69,093
Next
